Fascia iliaca compartment block for postoperative hip fracture pain: a systematic review and meta-analysis of randomized controlled trials Authors: Wenzhu Wang, Ping Zhang, Fen Cui, Xiang Wei, Zeyu Zhang, Haolin Fang, Jian Liu Published: 2026 ABSTRACT AbstractBackgroundThe fascia iliaca compartment block has been proposed to reduce postoperative pain and opioid consumption after hip fracture surgery; however, whether these effects translate into clinically meaningful benefits remains uncertain.MethodsPubMed, Embase, the Cochrane Central Register of Controlled Trials, and Wanfang Data were systematically searched for randomized controlled trials published through October 2025. The primary outcomes were cumulative opioid consumption within 24 h after surgery and resting pain scores at 24 h. Secondary outcomes included pain scores at 6 and 12 h, the 24-h pain–time area under the curve, time to first analgesic request, functional recovery, and adverse events. The minimum clinically important difference for postoperative analgesic consumption within 24 h was defined as 30 mg of oral morphine equivalents, and the minimum clinically important difference for pain scores was defined as 0.99 cm. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation framework.ResultsFourteen randomized controlled trials involving 1231 patients were included. Fascia iliaca compartment block significantly reduced 24-h opioid consumption (mean difference, − 11.07 mg; 95% confidence interval, − 15.34 to − 6.81; P < 0.00001) and resting pain scores at 24 h (mean difference, − 0.51 cm; 95% confidence interval, − 0.82 to − 0.21; P = 0.001). Pain scores at 6 and 12 h after surgery were also significantly reduced. However, apart from the pain score at 6 h post-surgery, the above results did not meet the pre-defined minimum clinically important difference. In addition, fascia iliaca compartment block prolonged the time to first analgesic request and reduced the incidence of opioid-related adverse events.ConclusionsFICB was associated with reductions in early postoperative pain and opioid consumption after hip fracture surgery; however, the clinical relevance of these benefits appears limited, except possibly for pain relief at 6 h postoperatively. Given the overall certainty of evidence ranging from very low to moderate, routine use of FICB may not be warranted, and further high-quality randomized controlled trials are needed to better define its analgesic efficacy and identify patients most likely to benefit.PROSPERO registration numberCRD420251069610.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-03892-y.Keywords: Nerve block, Hip fracture, Postoperative pain, Systematic review, Meta-analysis Introduction Hip fracture is one of the most common fractures among older adults [1], and effective postoperative pain management remains a major clinical challenge [2]. The complexity of pain following hip fracture surgery is largely attributed to the intricate innervation of the hip joint, which involves multiple neural pathways [3, 4]. The anterior capsule is primarily innervated by branches of the femoral nerve (FN) and, in some cases, the accessory obturator nerve (ON), while the ON also contributes to sensation in the inferomedial aspect of the joint. In contrast, the posterior capsule is mainly supplied by branches of the sciatic nerve. This complex and partially overlapping innervation may limit the effectiveness of single-site regional analgesic techniques. Multimodal analgesia has been shown to improve pain control after surgery, and it reduces the use of systemic opioids and improves patient satisfaction after hip fracture surgery [5, 6]. Within this framework, peripheral nerve blocks (PNBs) play a central role [7, 8]. The fascia iliaca compartment block (FICB) is designed to deliver local anesthetic (LA) into the fascia iliaca compartment, so it can block the FN, the lateral femoral cutaneous nerve, and sometimes the ON [9, 10]. Several randomized controlled trials (RCTs) have demonstrated the analgesic efficacy of FICB [11–14], and current guidelines suggest using FICBs for incision pain management in hip fracture surgery [15]. However, some RCTs suggest that FICB does not offer any additional benefits [16, 17]. Furthermore, a recent systematic review and network meta-analysis has suggested that the overall analgesic effect of FICB in hip fracture patients may be limited [18]. The discrepancies in the aforementioned research findings have prompted us to re-examine the true analgesic efficacy of FICB, with a particular focus on whether it offers substantial clinical benefits. The minimum clinically important difference (MCID) has been increasingly used to determine whether observed changes in patient-reported outcomes are meaningful from a clinical perspective [19]. In postoperative pain management, analgesic effects tend to be most pronounced in the early postoperative period, with diminishing incremental benefits over time, reflecting a nonlinear response pattern [20]. As a result, small differences observed at later time points may reach statistical significance but still fall below thresholds of clinical relevance. Importantly, statistically significant differences do not necessarily correspond to clinically meaningful improvements. Therefore, incorporating MCID into outcome assessment enables a more patient-centered evaluation of analgesic efficacy. Accordingly, the present systematic review and meta-analysis aimed to evaluate the effectiveness of FICB in patients undergoing hip fracture surgery, with a particular focus on whether the observed benefits reach clinically meaningful thresholds as defined by MCID. Methods This research protocol has been pre-registered in the PROSPERO database (registration number CRD420251069610). The initial registration date was June 7, 2025, and it was revised on June 25, 2025. The amendments included refinement of the criteria for quantitative synthesis, addition of risk-of-bias assessment, and clarification of heterogeneity-related analyses. All changes were made prior to data extraction and analysis. For more details, please see https://www.crd.york.ac.uk/PROSPERO/view/CRD420251069610. Our study was conducted strictly in accordance with the registration information. The conduct and reporting of this study follow the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. Search strategy A medical informatics expert (FC) designed the search strategy. We searched the Cochrane Central Register of Controlled Trials, Embase, PubMed, and the Wanfang database from their inception to October 30, 2025. The search strategy combined Medical Subject Headings (MeSH) with relevant free-text terms to identify studies addressing the key research questions of this review. The full search strategies are provided in Supplementary Tables 1–4. We manually screened the reference lists of all potentially eligible articles to find additional relevant studies. To identify ongoing or unpublished trials, we adapted the PubMed search strategy and applied it to five trial registries: ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry, the Chinese Clinical Trials Registry, the German Clinical Trials Registry, and the Indian Clinical Trials Registry. We also conducted supplementary searches in Google Scholar using topic-related keywords. After the initial search, we activated weekly automatic alerts in PubMed using the same search strategy to keep track of newly published studies. Inclusion criteria for study selection We included RCTs involving adults undergoing surgical treatment for hip fractures. Inclusion was restricted to RCTs to ensure a high level of evidence and minimize bias. The adult population was defined as patients aged ≥ 16 years. No restrictions were placed on patient comorbidities (e.g., cardiovascular disease, diabetes, or American Society of Anesthesiologists physical status), as these are common in the hip fracture population and reflect real-world clinical practice. Studies were eligible if ≥ 80% of participants met these criteria. Eligible studies included patients receiving either GA or neuraxial anesthesia (e.g., spinal or epidural anesthesia). Trials comparing single-injection FICB with sham block, placebo injection, or standard analgesic care were included. Continuous catheter techniques were excluded to reduce clinical heterogeneity associated with variations in infusion protocols, catheter duration, and local anesthetic dosing. All study groups were permitted to receive the same additional analgesic adjuvants (eg, epidural analgesia, intrathecal morphine, or local infiltration analgesia). Studies were required to report at least one of the following outcomes: total opioid consumption within the first 24 postoperative hours or pain scores at rest at 24 h after surgery. No language restrictions were applied. Exclusion criteria Studies were excluded if they involved nonhuman subjects or pediatric populations (< 16 years); or patients undergoing hip surgery for non-fracture indications (e.g., osteoarthritis or avascular necrosis). Studies evaluating FICB administered outside the perioperative setting (e.g., in the emergency department or ward prior to surgery) were excluded to ensure clinical comparability. We also excluded observational studies, retrospective analyses, conference abstracts without full text, duplicate publications, and studies with insufficient or non-extractable outcome data. Data extraction Two reviewers (WZW and PZ) independently extracted predefined data from each eligible study, including the first author, year of publication, surgical methods, sample size of each group, LA dose, anesthesia method (GA or neuraxial anesthesia), timing of FICB administration, postoperative analgesia regimen, and outcomes. When outcome data were presented only in graphical form, numerical values were extracted using GetData Graph Digitizer software (version 2.26). The discrepancies in data extraction were resolved through independent reassessment and discussion between WZW and PZ. If a consensus could not be reached, XW would make the final decision. Quality assessment The methodological quality of included RCTs was assessed using the Risk of Bias 2.0 (RoB2.0) tool across domains of randomization, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting [21]. The certainty of evidence for pooled outcomes was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework [22]. Evidence quality was rated as high, moderate, low, or very low. Confidence in effect estimates could be decreased by risk of bias, inconsistency, imprecision, indirectness, or publication bias. Conversely, confidence could be increased by a large effect size, adjustment for confounding factors, or the presence of a dose–response relationship. Risk-of-bias and GRADE assessments were conducted independently by WZW and PZ, with discrepancies resolved by consensus or adjudication by XW. Study outcomes Patients with hip fractures typically experience severe pain during the first postoperative day [23]. Accordingly, the primary outcomes were cumulative opioid consumption within 24 h after surgery and resting pain scores at 24 h. Secondary outcomes were categorized into 3 domains. Pain-related endpoints included pain scores at 6 and 12 h after surgery, the 24-h area under the curve (AUC) for pain intensity, and time to first analgesic request (hours). Functional recovery was assessed by time to first postoperative sitting or standing and length of hospital stay. Safety outcomes included composite opioid-related adverse events (nausea, vomiting, respiratory depression, urinary retention, pruritus and altered mental status) and nerve block–related complications (hematoma, organ injury, LA systemic toxicity, and block failure). All opioid doses were converted to oral morphine equivalents (OME; mg) according to the method described by Nielsen et al. [24]. MCID was established as 30 mg OME for 24—h opioid consumption [25]. All pain scores were converted to a 0–10 cm visual analog scale (VAS), with 0 cm indicating no pain and 10 cm representing the worst pain imaginable [26]. Within the 0–10 cm VAS, no universally accepted MCID has been established for acute postoperative pain [27]. We pre-set the MCID to 0.99 cm [28]. AUC analysis was used to characterize pain trajectories over the first 24 postoperative hours [29]. Statistical analysis Meta-analyses were conducted only when data were available from at least 3 studies. Statistical analyses were performed using Review Manager version 5.3 (Cochrane Collaboration) and Stata version 14.0. Continuous outcomes were summarized as mean differences (MDs) with 95% confidence intervals (CIs), and dichotomous outcomes as relative risks (RRs) with 95% CIs using the Mantel–Haenszel method. Statistical heterogeneity was assessed using Cochrane’s Q test (P ≤ 0.10 indicating statistical significance) and quantified with the I2 statistic. An I2 value greater than 50% was considered to indicate substantial heterogeneity. The 95% CIs for I2 were also examined to reflect the uncertainty in heterogeneity estimates, particularly given the limited number of included studies. A random-effects model was applied in the presence of significant heterogeneity; otherwise, a fixed-effects model was used. When substantial heterogeneity was observed for the primary outcomes, sensitivity analyses were performed according to the use of adjuvant drugs with LAs, the type of FICB (superior-inguinal FICB [S-FICB] vs inguinal FICB [I-FICB]), and the postoperative analgesic regimen (opioid-only vs multimodal analgesia). In addition, subgroup analyses were conducted according to the method of anesthesia (neuraxial anesthesia or GA), provided that at least three studies were available in each subgroup. When a meta-analysis included 10 or more studies, small-study effects were assessed visually using funnel plots and statistically using Egger’s linear regression test. If the 2-tailed P value for Egger’s test was less than 0.05, it was taken as a sign that there might be publication bias. Results We started with 2207 records from the database and registry using our search plan. After getting rid of duplicates, we had 613 studies left to look through. After checking the titles and abstracts, we picked 29 studies to read in full. Out of those, 14 studies fit our criteria. We also found 7 more records through Google Scholar and 6 more through checking references, but none of these fit our criteria. As of January 11, 2026, no new studies came up in our alert searches. So, we ended up with 14 studies for the meta-analysis (see Fig. 1) [11–14, 16, 17, 30–37]. Study flow diagram Baseline characteristics and risk of bias Table 1 shows the details and findings of the 14 studies we looked at. These trials, done between 2009 and 2024, had 1231 patients in total, with 651 getting the FICB treatment. The average age of all the patients was 74.3 years, and 62.6% were women, which matches what we know about people who get hip fractures [38]. All the main types of hip fracture surgeries were included. Only one study did not specify the anatomical approach of the FICB [33]; the rest all used the I-SICB. In the control groups, two studies used sham blocks [12, 16], while the remaining studies did not perform any operation. The number of people in each study varied from 21 to 231 [13, 37]. Ropivacaine was the only LA used, and dexamethasone was added in two studies [31, 34]. Nine studies used spinal anesthesia (SA), and five used GA [11, 32, 33, 35, 37]. Most of the time, the nerve blocks were given before surgery; one study gave the block after surgery [13], and another let it be done either before or after [33]. Four studies mentioned the use of multimodal analgesia postoperatively [13, 17, 31, 33], but two didn’t say what they used [30, 35]. Risk-of-bias assessments are summarized in Fig. 2. Most studies were judged to have a moderate risk of bias, primarily related to limitations in randomization procedures and outcome assessment. One study was rated as low risk [13], whereas another was considered high risk because of allocation based on medical record numbers and protocol deviations [33], and the remaining studies were rated as moderate risk of bias. Table 1Characteristics of included studies and reported outcomesAuthor/yearSurgeryGroupNumberIntervention drugsSurgical anesthesiaBlock timingPostoperative analgesiaOutcomesBang 2016 [13]Bipolar hemiarthroplastyI-FICB1040 mL 0.2% ropivacaineSAPostoperativeMultimodal analgesia: including oral, intravenous and rescue analgesia①②④⑧No block11NoneChen 2017 [30]Hip replacementI-FICB2230 mL 0.25% ropivacaineSAPreoperativeNot reported②③④⑧No block22NoneDai 2024 [11]Not reportedI-FICB3130 mL 0.33% ropivacaineGAPreoperativeFlurbiprofen was administered at a dose of 1–2 mg/kg①②③⑦⑧No block31NoneDiakomi 2014 [14]Hip fracture surgical repairI-FICB2140 mL 0.5% ropivacaineSAPreoperativePCA: morphine 1 mg bolus dose with a 10-min lockout interval①⑤No block21NoneDiakomi 2020 [12]Intramedullary nailing, hemiarthroplasty and screw fixationI-FICB9140 mL 0.5% ropivacaineSAPreoperativePCA: a 10 mg tramadol bolus dose and the lockout interval set to 10 min①②③⑤⑥Sham block912 mL 0.9% saline solutionHao 2022 [31]Hemiarthroplasty, total hip arthroplasty, and PFNAI-FICB6030 mL of a mixture containing 0.33% ropivacaine, 1% lidocaine, and 5 mg dexamethasoneSAPreoperativeIntramuscular parecoxib 40 mg for 3 days, then to oral celecoxib 200 mg after 3 days. Morphine was offered if analgesia was inadequate②③⑦⑧No block60NoneKacha 2018 [16]Dynamic hip screw Surgery, Austin Moore Prosthesis, Bipolar Prosthesis, acetabular platingI-FICB5030 mL 0.25% ropivacaineSAPreoperativeInjection diclofenac sodium 1.5 mg/kg②④⑤Sham block5030 mL 0.9% saline solutionRuan 2021 [32]Hip replacementI-FICB6030—40 mL 0.2% ropivacaineGAPreoperativePCA: Total amount of 1.5 μg/kg sufentanil②③④No block56NoneSchulte 2020 [33]Screw fixation, Cephalomedullary nail, ArthroplastyFICB5745—60 mL 0.375% ropivacaineGABefore or after surgeryMultimodal analgesia: intravenous or oral pain medications, both opioid and nonopioid①②⑦No block40NoneWang 2023 [34]HemiarthroplastyI-FICB5230 mL of a mixture containing 0.375% ropivacaine and 5 mg of dexamethasoneSAPreoperativePCA: sufentanil 150 μg①⑤⑦⑧No block52NoneXu 2020 [9, 35]Internal fixationI-FICB3630 mL 0.4% ropivacaineGAPreoperativeNot reported②③⑧No block36NoneYamamoto 2019 [17]Bipolar hemiarthroplasty, internal fixationI-FICB2540 mL 0.25% ropivacaineSAPreoperativeloxoprofen sodium 60 mg orally and/or diclofenac sodium suppository 25 mg, on request②③④⑥⑧No block28NoneYun 2009 [36]Bipolar hemiarthroplasty, closed reduction and internal fixation with a compression hip screw, and total hip replacement arthroplastyI-FICB2030 mL 0.375% ropivacaineSAPreoperativeMeperidine 25 mg/0.5 mL in normal saline 50 mL intravenous①②③⑤No block20NoneZhu 2022 [37]InterTAN intramedullary nail, and PFNAI-FICB11630—40 mL 0.2% ropivacaineGAPreoperativePCA: Total amount of fentanyl 0.5 μg/kg②③⑧No block115NoneOutcome: ①24 h opioid consumption (oral morphine equivalents) ②Pain score at rest at 24 h postoperatively ③Pain score at rest at 6 h postoperatively ④Pain score at rest at 12 h postoperatively ⑤The time to first rescue analgesia ⑥The time to first sitting/standing postoperatively ⑦The length of hospital stay ⑧Opioid-related adverse effects ⑨Complications related to nerve blocksAbbreviations: GA general anesthesia, I-FICB infrainguinal fascia iliaca compartment block, PCA patient-controlled analgesia, PFNA proximal femoral nail antirotation, SA spinal anesthesia Characteristics of included studies and reported outcomes Outcome: ①24 h opioid consumption (oral morphine equivalents) ②Pain score at rest at 24 h postoperatively ③Pain score at rest at 6 h postoperatively ④Pain score at rest at 12 h postoperatively ⑤The time to first rescue analgesia ⑥The time to first sitting/standing postoperatively ⑦The length of hospital stay ⑧Opioid-related adverse effects ⑨Complications related to nerve blocks Abbreviations: GA general anesthesia, I-FICB infrainguinal fascia iliaca compartment block, PCA patient-controlled analgesia, PFNA proximal femoral nail antirotation, SA spinal anesthesia Risk of bias domains Primary outcome A total of 7 studies reported total opioid consumption within the first 24 postoperative hours [11–14, 33, 34, 36]. These studies included 282 patients in the FICB group and 265 patients in the control group. Compared with the control group, the FICB group demonstrated a reduction of 11.07 mg in OME (95% CI, − 15.34 to − 6.81; I2 = 88% [95% CI 80–93%]; P < 0.00001 for heterogeneity; Z = 5.09, P < 0.00001 for overall effect; Fig. 3A). Although this difference was statistically significant, it did not reach the prespecified MCID. Sensitivity analyses showed that when only studies using LA alone were included, the FICB group had a reduction of 10.44 mg in OME compared with the control group (95% CI, − 15.33 to − 5.56; I2 = 90% [95% CI 82–95%]; P < 0.00001 for heterogeneity; Z = 4.19, P < 0.00001 for overall effect; Supplemental Fig. 1). When the analysis was restricted to studies using I-FICB, opioid consumption was reduced by 12.71 mg in OME in the FICB group (95% CI, − 16.33 to − 9.09; I2 = 78% [95% CI 56–89%]; P = 0.0003 for heterogeneity; Z = 6.88, P < 0.00001 for overall effect; Supplemental Fig. 2). Only two studies [13, 33] used postoperative multimodal analgesia, and only two studies [11, 33] employed GA; therefore, no further data synthesis was performed for these two results. Forest plot of primary outcomes A total of 12 studies reported resting pain scores at 24 h after surgery [11–13, 16, 17, 30–33, 35–37]. These studies included 578 patients in the FICB group and 560 patients in the control group. Compared with the control group, FICB was associated with a reduction in pain scores of 0.51 cm (95% CI, − 0.82 to − 0.21; I2 = 86% [95% CI 80–93%]; P < 0.00001 for heterogeneity; Z = 3.28, P = 0.001 for overall effect; Fig. 3B). Although this difference was statistically significant, it did not reach the prespecified MCID. Sensitivity analysis incorporating only LAs revealed that FICB reduced pain scores by 0.44 cm (95% CI, –0.74 to –0.14; I2 = 84% [95% CI 72–90%], P value for heterogeneity test < 0.00001; overall effect test Z = 2.83, P for overall effect = 0.005; Supplemental Fig. 3). When the analysis was restricted to studies using I-FICB, pain scores were reduced by 0.65 cm in the FICB group (95% CI, − 0.90 to − 0.40; I2 = 79% [95% CI 63–88%]; P < 0.00001 for heterogeneity; Z = 5.01, P < 0.00001 for overall effect; Supplemental Fig. 4). In sensitivity analyses restricted to studies using multimodal analgesia, there was no statistically significant difference in pain scores between the FICB and control groups (MD, − 0.34 cm; 95% CI, − 1.29 to 0.61; I2 = 95% [95% CI 87–98%]; P < 0.00001 for heterogeneity; Z = 0.70, P = 0.48 for overall effect; Supplemental Fig. 5). Subgroup analysis showed that in the SA subgroup, FICB reduced postoperative rest pain at 24 h (MD, − 0.63 cm; 95% CI, − 1.06 to 0.20; I2 = 85% [95% CI 70–92%]; P < 0.00001 for heterogeneity; Z = 2.90, P = 0.004 for overall effect; Supplemental Fig. 6); while in the GA subgroup, FICB did not affect postoperative rest pain at 24 h (MD, − 0.36 cm; 95% CI, − 0.84 to 0.12; I2 = 86% [95% CI 70–94%]; P < 0.00001 for heterogeneity; Z = 1.47, P = 0.14 for overall effect; Supplemental Fig. 6). Secondary outcome Secondary analgesic outcomes Pooled results from 9 studies (n = 920) reported resting pain scores at 6 h after surgery [11, 12, 17, 30–32, 35–37]. Compared with the control group, the FICB group demonstrated a reduction in pain scores of 1.43 cm (95% CI, − 2.15 to − 0.70; I2 = 97% [95% CI 96–98%]; P < 0.00001 for heterogeneity; Z = 3.86, P = 0.0001 for overall effect; Table 2 and Supplemental Fig. 7), exceeding the MCID. Table 2Meta analysis results of secondary outcomesIndicatorsNumber of patientsHeterogeneity test resultsEffect modelMD or RR (95%CI)PDifference valueFICB ControlI2 (%) PPain scores at rest at 6 h postoperatively46145997< 0.00001Random−1.43 (−2.15, −0.70)0.0001Pain scores at rest at 12 h postoperatively16716793< 0.00001Random−0.78 (−1.39, −0.17)0.01Time for the first rescue analgesia23423397< 0.00001Random2.22 (1.18, 3.26)< 0.0001Length of hospital stay200183770.005Random−0.84 (−1.68, 0.00)0.05Cumulative opioid-related adverse events23424000.75Fixed0.59 (0.44, 0.78)0.0002Abbreviations: FICB Fascia iliaca compartment block, RR Relative ratio, MD Mean difference Meta analysis results of secondary outcomes Abbreviations: FICB Fascia iliaca compartment block, RR Relative ratio, MD Mean difference Pooled results from 5 studies (n = 334) [13, 16, 17, 30, 32] showed that FICB reduced resting pain scores by 0.78 cm at 12 h postoperatively (95% CI, − 1.39 to − 0.17; I2 = 93% [95% CI 85–97%]; P < 0.00001 for heterogeneity; Z = 2.49, P = 0.01 for overall effect; Table 2 and Supplemental Fig. 8). However, this reduction did not reach the MCID. The AUC for resting pain scores over the first 24 h postoperative was 50.16 ± 30.24 cm·h in the FICB group and 64.67 ± 24.77 cm·h in the control group. Although the AUC value was numerically lower in the FICB group across analyses, the difference did not reach statistical significance (P = 0.212). Detailed results are provided in Supplemental Fig. 9. Pooled results from 5 studies (n = 467) [12, 14, 16, 34, 36] showed that FICB delayed the time to first analgesic request by 2.22 h compared with the control group (95% CI, 1.18 to 3.26; I2 = 97% [95% CI 95–98%]; P < 0.00001 for heterogeneity; Z = 4.20, P < 0.0001 for overall effect; Table 2 and Supplemental Fig. 10). Recovery indicators Only 2 studies reported data on time to first postoperative sitting or standing [12, 17]. Consequently, a pooled analysis for this outcome was not performed. Four studies (n = 383) [11, 31, 33, 34] showed no significant difference in length of hospital stay between groups (MD = − 0.84 days; 95% CI, − 1.68 to 0.00; I2 = 77% [95% CI 34–92%]; P = 0.005 for heterogeneity; Z = 1.96, P = 0.05 for overall effect; Table 2 and Supplemental Fig. 11). Safety indicators Pooled results from 7 studies (n = 474) [11, 13, 17, 30, 31, 34, 37] showed that FICB reduced the incidence of opioid-related adverse events from 35.8% to 21.4% (RR, 0.59; 95% CI, 0.44 to 0.78; I2 = 0%; P = 0.75 for heterogeneity; Z = 3.71, P = 0.0002 for overall effect; Table 2 and Supplemental Fig. 12). Only Hao et al. reported a nerve block–related complication, consisting of a single case of hematoma at the puncture site [31]. Publication bias and quality of evidence Among the pooled analyses, only the postoperative 24-h resting pain score was derived from more than 10 studies. Funnel plot inspection and Egger’s test revealed no evidence of publication bias (P = 0.327; Supplemental Fig. 13 and Fig. 14). The GRADE rating was judged to be moderate for opioid-related adverse events and low for pain scores at rest at 12 h after surgery. All other outcomes were rated as very low. The main reason was that most studies failed to adequately implement allocation concealment, and the pooled estimates of the outcome measures showed significant heterogeneity. See Table 3 for details. Table 3Summary of the quality of evidence (GRADE) for all statistically pooled outcomesCertainty assessment№ of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsCertaintyThe total consumption of analgesic drugs within 24 h postoperatively7randomised trialsseriousavery seriousbnot seriousnot seriousnone⨁◯◯◯Very low a,bPain scores at rest 24 h after surgery12randomised trialsseriousavery seriousbnot seriousnot seriousnone⨁◯◯◯Very low a,bPain scores at rest 6 h after surgery9randomised trialsseriousavery seriousbnot seriousnot seriousnone⨁◯◯◯Very low a,bPain scores at rest 12 h after surgery5randomised trialsnot seriousvery seriousbnot seriousnot seriousnone⨁⨁◯◯Low bThe time to first analgesic request5randomised trialsseriousavery seriousbnot seriousnot seriousnone⨁◯◯◯Very low a,bThe length of hospital stay4randomised trialsvery seriouscvery seriousbnot seriousSeriousdnone⨁◯◯◯Very low b,c,dopioid-related adverse events7randomised trialsseriousanot seriousnot seriousnot seriousnone⨁⨁⨁◯ Moderate aaMost studies did not employ allocation concealment (especially when the outcome indicator was a subjective test indicator)bThere is high heterogeneity among the included studiescSeveral studies employed incorrect randomization methods or failed to implement adequate allocation concealmentdFew patients were included and the 95% confidence interval crossed the line of ineffectiveness Summary of the quality of evidence (GRADE) for all statistically pooled outcomes ⨁◯◯◯ Very low a,b ⨁◯◯◯ Very low a,b ⨁⨁◯◯ Low b ⨁◯◯◯ Very low a,b ⨁◯◯◯ Very low b,c,d aMost studies did not employ allocation concealment (especially when the outcome indicator was a subjective test indicator) bThere is high heterogeneity among the included studies cSeveral studies employed incorrect randomization methods or failed to implement adequate allocation concealment dFew patients were included and the 95% confidence interval crossed the line of ineffectiveness Discussion This systematic review and meta-analysis suggest that the use of FICB within 24 h after hip fracture surgery is associated with statistically significant reductions in opioid consumption and postoperative pain scores. However, the magnitude of these effects was generally small and did not reach clinically meaningful thresholds, except for pain reduction observed in the early postoperative period (within 6 h). In addition, FICB was associated with a prolonged time to first request for rescue analgesia and a reduced incidence of opioid-related adverse events. The overall certainty of the evidence ranged from very low to moderate. Fadhlillah et al. studied the analgesic effect of perioperative FICB, focusing primarily on the preoperative period. The studies they actually included all used the localized method to implement FICB, and the control group included other PNBs. This might lead to more confusing results and make the effects of FICB on postoperative pain appear smaller [39]. We included only patients who received FICB in the operating room, preoperative preparation room, or post-anesthesia recovery room, with ultrasound-guided FICB, and compared them to those who received a sham block or no block. Most of the studies included by Hong et al. were also conducted in the emergency department, including continuous infusion via catheter implantation, with the study cutoff point being 72 h post-procedure [40]. We focused exclusively on a single FICB procedure and assessed pain during the first 24 h post-procedure, as this period typically represents the most intense pain. Importantly, our meta-analysis did not demonstrate a clinically meaningful reduction in pain scores or opioid dosage within 24 h postoperatively. This indicates that, while FICB provides measurable analgesic effects, the magnitude of benefit may be insufficient to translate into clinically meaningful improvement during this period. Consistent with this finding, a previous RCT showed that ultrasound-guided injection of 40 ml of 0.5% ropivacaine provided analgesia for about 6—7 h and improved early postoperative recovery quality, but the effect gradually diminished thereafter [41]. Previous studies have shown inconsistencies between decreased pain scores and reduced opioid consumption [42, 43]. This may explain why clinically meaningful benefits were observed only in the early postoperative phase. MCID values for postoperative pain are not fixed and may vary depending on baseline pain severity and patient characteristics [44–47]. Previous studies have reported MCID thresholds of 0.99, 1.3 or 1.5 cm [28, 48–50], while only a few studies have used a threshold of 2.0 cm [51]. Vollert et al. reported that the MCID for pain at rest was approximately 1.0 cm in patients with mild pain and 2.1 cm in those with severe pain [45]. Given that postoperative pain intensity in hip fracture patients typically decreases over time and is often in the mild-to-moderate range at later time points (e.g., 12–24 h), selecting the MCID threshold (0.99 cm) is clinically justifiable. Importantly, the observed effect size was below the pre-defined threshold, and even lower than the MCID range of 1.3–2.0 cm reported in other studies. This supports the robustness of the conclusion that the clinical benefit is limited, and this finding is not sensitive to the choice of threshold. In our meta-analysis, patients undergoing hip surgery for arthritis or avascular necrosis were excluded. These patients often suffer from chronic pain and are more prone to central sensitization [52]. Despite the limited magnitude of analgesic benefit, FICB may still offer clinical value in certain contexts. In particular, the reduction in opioid-related adverse events and the prolongation of time to first analgesic request suggests a favorable safety profile. These advantages may be especially relevant for elderly and frail patients, who are more susceptible to opioid-related complications [53]. In emergency departments, pre-hospital emergency care, or settings with limited monitoring capabilities, FICB may also contribute to improved safety and simplified care pathways [54]. The impact of FICB on functional recovery remains uncertain. Due to limited reporting, functional outcomes such as time to first postoperative sitting or standing could not be quantitatively synthesized. This is clinically important, as improvements in pain scores do not necessarily translate into meaningful functional benefits, such as earlier mobilization or enhanced rehabilitation. In addition, FICB may affect quadriceps muscle strength, particularly at higher LA concentrations, which could potentially delay mobilization and increase the risk of falls [41]. Therefore, while FICB remains a widely used and clinically useful technique, its relative efficacy compared with other PNBs requires further clarification. Some studies have compared pericapsular nerve group (PENG) block with FICB in hip surgery. Compared to FICB, PENG block may provide better analgesia, reduce opioid dosage, have less impact on quadriceps muscle strength, and improve functional comfort [55–58]. Moreover, the quadratus lumborum block and erector spinae plane block is thought to provide enhanced analgesia due to their proximity to the spinal cord [59–61]. These findings suggest that, while FICB remains a widely used and effective analgesic option, alternative regional techniques may offer additional benefits in certain settings. Substantial heterogeneity was consistently observed, with I2 values frequently exceeding 80%. Importantly, the corresponding 95% CIs for I2 were generally narrow and remained within a high range for the vast majority of outcomes, suggesting that the observed heterogeneity is unlikely to be solely attributable to random variation and instead reflects genuine between-study differences. Several factors may explain this significant and consistent heterogeneity. Methodological factors include differences in study design and outcome assessment. The intrinsic characteristics of FICB represent an additional important source of heterogeneity, including the type of LA, concentration–volume combinations, adjuvant drugs, and whether the block is performed in I-FICB or S-FICB [62, 63]. Clinical factors, such as anesthesia type, postoperative analgesic regimens, patient characteristics, and baseline pain intensity, may also influence treatment effects [5, 64, 65]. Notably, subgroup analyses did not identify a single dominant source of heterogeneity, suggesting that the observed variability is multifactorial. This study has several important methodological and analytical limitations. First, although only RCTs were included, the overall certainty of the evidence was low to very low according to the GRADE framework, mainly due to the risk of bias, inconsistency, and imprecision. Second, significant heterogeneity was observed in most outcome measures (I2 typically > 80%), and residual heterogeneity remained unexplained despite subgroup and sensitivity analyses, which may reflect clinical and methodological differences among studies. Third, the limited number of studies for some outcome measures restricted further analysis and reduced statistical power; furthermore, the wide confidence intervals for I2 in very few analyses indicated uncertainty in the estimation of heterogeneity. Fourth, the choice of the MCID threshold itself was uncertain. Although a lower threshold was used based on the clinical context, this may have led to an overestimation of clinical relevance. However, the observed effect size was still lower than the commonly reported MCID value, supporting the robustness of our conclusions. Fifth, most trials used non-blocked or standard treatment rather than sham-operated controls, which may have led to procedural and detection biases, especially in subjective outcomes such as pain scores [66]. Sixth, inconsistent reporting of key clinical variables (such as comorbidities, fracture type, and rehabilitation protocols) limits more detailed analysis and may lead to heterogeneity. Seventh, no studies specifically evaluate S-FICB, thus its effectiveness cannot be directly assessed. Finally, limited functional outcome data prevent a full assessment of functional recovery; since pain relief does not necessarily translate into functional benefit, this reduces clinical interpretability. Conclusions FICB was associated with statistically significant reductions in postoperative pain and opioid consumption within 24 h after hip fracture surgery; however, the magnitude of these effects was generally small and of limited clinical relevance, with only 6-h pain scores demonstrating a potentially meaningful benefit. These findings suggest that routine use of FICB in all patients with hip fractures may not be warranted. Given that the overall certainty of evidence ranged from very low to moderate, the strength of these conclusions remains limited and should be interpreted with caution. Further high-quality RCTs are required to better define the postoperative analgesic efficacy of FICB and to identify the patient populations most likely to benefit. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements Not applicable. Authors’ contributions WZW and PZ were responsible for literature screening, data extraction, risk of bias assessment, and data analysis, and drafted the initial manuscript. FC conceived and designed the literature search strategy and provided suggestions for manuscript revisions. XW served as the third reviewer and arbitrator. ZYZ polished the manuscript, JL and HLF conceived and revised this article, with JL providing financial support. The final version of the manuscript has been read and approved by all authors. Funding This research was supported by grants from Key R&D Program of Jining (2025YXNS140). Funders had no role in the study design, data extraction, and interpretation. Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate This study is a systematic review and meta-analysis of previously published randomized controlled trials. No new participants were enrolled, and no individual-level patient data were collected. Therefore, ethical approval and informed consent were not required. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wenzhu Wang and Ping Zhang contributed equally to this work and should be considered co-first authors. Contributor Information Haolin Fang, Email: fanghaolin0105@sina.com. Jian Liu, Email: Liujian198243@126.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement All data generated or analyzed during this study are included in this published article and its supplementary information files.